Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Date:3/7/2013

ns in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

Non-GAAP Financial Measures This press release provides financial measures for net loss and basic and diluted loss per share that exclude specifically identified non-routine items, and are therefore not calculated in accordance with accounting principles generally accepted in the United States ("GAAP"). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance that enhances management's and investors' ability to evaluate Cadence's operating results.

These non-GAAP financial measures are not intended to be used in isolation and should not be considered a substitute for any other performance measure determined in accordance with GAAP. Investors and potential investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool, including that other companies may calculate similar non-GAAP financial measures differently than Cadence, limiting their usefulness as a comparative tool. Cadence compensates for these limitations by providing specific information regarding the GAAP amount excluded from the non-GAAP financial measures. Cadence further compensates for the limitations of its use of non-GAAP financial measures by presenting comparable GAAP measures more prominently. Investors and potential investors are encouraged to review the calculation of non-GAAP financial measures contained within this press release w
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
4. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
5. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
6. Cadence Pharmaceuticals to Host Analyst and Investor Day
7. Cadence to Open Finished Medical Device Facility
8. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
9. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... GSI Group Inc. (NASDAQ: GSIG ... and supplier of precision photonics and motion control components ... technology markets, today reported financial results for the fourth ... financial results in this press release are GAAP measures ... fourth quarter of 2014, GSI generated revenue of $94.0 ...
(Date:3/4/2015)... Calif. , March 4, 2015  Nevro Corp. ... that has developed and commercialized an innovative, evidence-based neuromodulation ... that it will release financial results for the fourth ... on Wednesday, March 18, 2015. Company management will host ... (4:30 p.m. Eastern Time) on Wednesday, March 18, 2015. ...
(Date:3/4/2015)... The March 3, 2015, order from the Federal Drug Administration ... labels to clarify the drugs, intended use and warn about ... to protect the public from injury from these products, according ... Hanly Conroy . The order says that the ... currently taken by millions of U.S. men – are approved ...
Breaking Medicine Technology:GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 10GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 11GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 12GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 13GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 14GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 15GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 16GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 17GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 18GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 19GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 20GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 21GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 23GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 24GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 25GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 26GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 27GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 28GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 29GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 30GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 31GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 32GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 33Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2
... , PALO ALTO, Calif., Dec. 2 Varian, Inc. (Nasdaq: ... with the U.S. Securities and Exchange Commission its Annual Report on ... This Annual Report may be accessed through the Company,s web site ... on "10-K" in the table shown. Stockholders may receive a ...
... , NEW YORK, Dec. 2 ... is available in its catalogue: , Pharmaceutical ... http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html , Global pharma ... competition in generic markets, rising cost of new product ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5
(Date:3/4/2015)... 2015 Imagine No Malaria’s 2014 World Malaria ... Innovator Award , an honor given to nonprofit causes that ... Nonprofit Technology Conference (NTC15) in Austin, Texas. The ... Church in Austin, was on hand for the presentation; she ... Malaria. , Imagine No Malaria was one of five finalists ...
(Date:3/4/2015)... Orlando, Florida (PRWEB) March 04, 2015 ... includes a 6.2 mile swim, 261.4 mile bike, and ... with a total time of 24:45:45. , "This race ... thankful to my wonderful team and sponsors for supporting ... , Ultraman Florida 2015 had a total of 40 ...
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 Cook For Your Life ... teaches healthy cooking to people touched by cancer, is ... The program, run by founder Ann Ogden, will be ... Management. The unique partnership will expand the program from ... CFYL in 2007. After going through her own cancer ...
(Date:3/4/2015)... With the growing influence of movies, television, video games and ... adults, combined with the increasingly frantic lifestyle of modern parents, ... up with what kids are into these days. It seems ... daily basis. , The same is also true for drugs ... to discreetly talk about them, are constantly changing. These tips ...
Breaking Medicine News(10 mins):Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2
... Closed-Chest, Bypass Surgery; Created Robotic Bypass ... Reproducibility of Procedure and Decrease Learning Curve ... Cardica, Inc.,(Nasdaq: CRDC ) today ... is innovating robot-assisted,minimally-invasive cardiac bypass surgery with ...
... 28 CYNACON / OCuSOFT(R),(OCuSOFT(R), Inc.), a ... to ophthalmologists and optometrists, is pleased to,announce ... OCuSOFT(R) Lid Scrub(TM),Plus is now available in ... *(Photo Caption: OCuSOFT(R) Lid Scrub(TM) PLUS), ...
... access to insurance tend to have healthier children , , WEDNESDAY, ... care in America varies widely from state to state, ... likelihood of living long and healthy lives. , That,s the ... a private foundation that seeks to promote better health care ...
... /PRNewswire-FirstCall/ - Innolife Pharma, Inc.,(Other OTC:INNP.PK - ( ... that,they have unveiled their new website. This new ... more comfortable feeling with regards to what,INNP is ... About Innolife Pharma Inc., --------------------------, Innolife ...
... Glycoproducts International,Inc., a provider of nutritional ... jury sitting in the Northern District of ... that Glycoproducts International, Inc.,committed patent infringement of ... to Mannatech,s AMBROTOSE(R) technology., The jury ...
... Histologies Achieved, Improvement in Overall Survival when ... The type of non-small,cell lung cancer (NSCLC) patients have ... outcome according to the results of a major,study published ... study was announced by Eli Lilly and Company., ...
Cached Medicine News:Health News:Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardica's C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons 2Health News:Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardica's C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons 3Health News:Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardica's C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons 4Health News:CYNACON / OCuSOFT(R) Announces OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies 2Health News:States' Scorecard Finds Big Differences in Kids' Health Care 2Health News:States' Scorecard Finds Big Differences in Kids' Health Care 3Health News:Jury Rules in Favor of Glycoproducts International, Inc. 2Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 2Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 3Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 4Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 5Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 6Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 7Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 8Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 9Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 10Health News:Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer 11
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: